Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIT: Intrathecal Trastuzumab in HER2+ Breast Cancer with Carcinomatous Meningitis
NCT01373710Phase 2Completed
- Sponsor
- Institut Curie
- Start
- May 2011
- Primary completion
- Apr 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab in breast cancer, Carcinomatous Meningitis (CM), sponsored by Institut Curie. Started May 2011; status: completed.
02
Drugs
03
Conditions
breast cancerCarcinomatous Meningitis (CM)
Beyond the preview
Go deeper on NCT01373710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01373710.